Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Identification and Management of High Risk Squamous Cell Carcinoma (SCC)
Description
The presentation focuses on high-risk squamous cell carcinoma (SCC), particularly regarding recurrence and metastasis, which are critical concerns for healthcare providers. The speaker illustrates case examples of patients, including a liver transplant recipient and an immunosuppressed individual, highlighting the nuances of managing these high-risk cases. Key points include the challenges of determining high-risk features, the importance of identifying ‘findable disease,’ and the potential for using imaging and biopsy techniques to guide treatment. Staging systems like the Brigham and Women’s criteria and modifications to the AJCC are discussed, emphasizing the need for accurate identification of risk factors, including patient-specific variables like immunosuppression, which complicate treatment outcomes. The speaker also stresses the necessity of interdisciplinary collaboration in managing high-risk populations and explores the implications of emerging therapies, such as immunotherapy. Additionally, the practice of using perineural invasion as a high-risk marker is detailed, with a focus on its impact on treatment decisions and patient surveillance. Overall, the presentation advocates for improved awareness and proactive strategies in addressing high-risk SCC to enhance patient care.
View moreConclusions
- High-risk squamous cell carcinoma (SCC) is primarily characterized by the risk of recurrence and metastasis.
- Not all patients presenting with SCC show evidence of metastatic disease upon initial evaluation.
- Immunosuppressed patients, such as those who are transplant recipients, are at increased risk for aggressive SCC.
- Staging systems are essential in identifying at-risk SCC patients, and risk factors significantly influence outcomes.
- Pathologic assessments during definitive surgery often reveal previously undocumented high-risk features that necessitate changes in management.
- Perineural invasion (PNI) is a critical high-risk feature that alters treatment and surveillance strategies for SCC patients.
- Immunotherapy has shown promise in treating high-risk SCC, particularly among immunocompromised patients, but further data is needed to optimize its use.
- Frequent multidisciplinary collaboration is crucial for effectively managing high-risk SCC patients and improving care outcomes.
- Regular clinical surveillance and imaging may be required based on identified risk factors, especially in high-risk populations.
- Cancer Res. 2019;79(12):3011-3027. doi:10.1158/0008-5472.CAN-19-0458
- Jambusaria-Pahlajani et al 2013 JAMA Derm
- Collins, M et al Derm Surg 2019
- Totonchy, M et al Derm Surg 2021
- Ruiz et al JAAD 2019
- Tam, S., Yao, C. M. K. L., Amit, M., Gajera, M., Luo, X., Treistman, R., Khanna, A., Aashiq, M., Nagarajan, P., Bell, D., El-Naggar, A., Migden, M., & Wong, M. JAMA Otolaryngol Head Neck Surg. 2020;146(2):128-135.
- JAAD 2023